Raja Ramachandran (राजा) (@raja_1980) 's Twitter Profile
Raja Ramachandran (राजा)

@raja_1980

Vegetarian, #Kidney Doctor, Associate Professor @ PGIMER, Chandigarh, India

ID: 373502699

linkhttp://pgimer.edu.in calendar_today14-09-2011 17:58:26

4,4K Tweet

4,4K Followers

1,1K Following

Dr Priti MD,FASN🇮🇳 (प्रिति) (@priti899) 's Twitter Profile Photo

🚨 Hot off the press! 🚨 ✔️Baseline parameters of the India-wide Glomerular Disease Network (iTANGIBLE) just got published! 🏥📊 🔥Have a look at the vast spectrum of glomerular diseases across our country. 🌟 Amazing team, great work—loved being a part of it! Many more

🚨 Hot off the press! 🚨 ✔️Baseline parameters of the India-wide Glomerular Disease Network (iTANGIBLE) just got published! 🏥📊

🔥Have a look at the vast spectrum of glomerular diseases across our country.
🌟 Amazing team, great work—loved being a part of it!
Many more
Raja Ramachandran (राजा) (@raja_1980) 's Twitter Profile Photo

Even among the greats, there are few innings that truly distinguish them. Chennai (and perhaps Sydney) was one such innings for Sachin. Sachin Tendulkar will always remain an underestimated strategist. His decision regarding MSD (over Yuvi) in 2011-a glimpse of this.

Vivekanand Jha | विवेकानन्द झा (@vjha126) 's Twitter Profile Photo

Presenting #iTANGIBLE - Indian collaborative 2 study primary glom diseases. ➡️ The first such cohort in the developing (majority) world ➡️ To understand disease phenotypes in Indian context kireports.org/article/S2468-… Funded by ICMR Raja Ramachandran (राजा) Dr Priti MD,FASN🇮🇳 (प्रिति) Dr Prof Manisha Sahay

Vivekanand Jha | विवेकानन्द झा (@vjha126) 's Twitter Profile Photo

➡️ establishes platform for studying disease course, treatment patterns, and outcomes of GNs ➡️ with consent for contact re clinical trials and biobanking, offers recruitment potential 4 studies investigating emerging therapies ➡️ Collaboration w/ estd international registries

Arvind Canchi (Conjeevaram)🇮🇳 (@arvindcanchi) 's Twitter Profile Photo

MN Hybrid therapy 👉 oral pred (starting at 60mg, tapering to 5 mg by month six), oral cyclophosphamide (150 mg for 1 wk foll by 100mg until month 2), and rituximab (1 g was given day 0, followed by a 2nd dose btw days 15-45, & a 3rd dose btw days 90-180) indianjnephrol.org/rituximab-cycl…

MN Hybrid therapy 👉 oral pred (starting at 60mg, tapering to 5 mg by month six), oral cyclophosphamide (150 mg for 1 wk foll by 100mg until month 2), and rituximab (1 g was given  day 0, followed by a 2nd dose btw days 15-45, & a 3rd dose btw days 90-180)
indianjnephrol.org/rituximab-cycl…
Deepak Prabhu (@ragiiing_bull) 's Twitter Profile Photo

Suprabhat ☀️ 🌄 🌞 ☀️ 🌄 🌞 ☀️ Bhagwan welcomes his childhood friend Sudama and is mighty satisfied with his humble offering of poha.

Raja Ramachandran (राजा) (@raja_1980) 's Twitter Profile Photo

As a cricket enthusiast never have been so happy for a country other than my own. I am sure this is the emotion with most cricket lovers from India.

As a cricket enthusiast never have been so happy for a country other than my own. I am sure this is the emotion with most cricket lovers from India.
Vivekanand Jha | विवेकानन्द झा (@vjha126) 's Twitter Profile Photo

Listen to Dr Vasistha Tatapudi of from NYU Langone Health focusing on the use of pig kidneys in humans - the rationale, immunological challenges, and genetic modifications involved in overcoming hyperacute rejection. youtu.be/pbumiUjck1I?si… Kamal D Shah Vijay Kher N Gopalakrishnan

Vivekanand Jha | विवेकानन्द झा (@vjha126) 's Twitter Profile Photo

New study: NOACs like apixaban safe & effective for short-term prevention of blood clots in primary membranous nephropathy patients with low albumin—no VTEs, low bleeding risk. Promising alternative to warfarin! #Nephrology #VTE #PatientCare indianjnephrol.org/apixaban-in-pr… Raja Ramachandran (राजा)

Vivekanand Jha | विवेकानन्द झा (@vjha126) 's Twitter Profile Photo

NOACs offer a practical solution for PMN patients at high risk of thrombosis—less monitoring, fewer clinic visits, and good safety profile, even in low-resource settings. More research needed, but early results are encouraging! #KidneyHealth #Anticoagulation

Marco Allinovi (@marcoallinovi) 's Twitter Profile Photo

Patients with membranous nephropathy treated with rituximab exhibit enhanced drug clearance due to urinary loss (rituximab underexposure), particularly in those with reduced eGFR and non-selective proteinuria. NDT doi.org/10.1093/ndt/gf…

Patients with membranous nephropathy treated with rituximab exhibit enhanced drug clearance due to urinary loss (rituximab underexposure), particularly in those with reduced eGFR and non-selective proteinuria. <a href="/NDTsocial/">NDT</a>
doi.org/10.1093/ndt/gf…